PRL04 Dermatology Relevant National Patient Safety Goals and Risks with AI-Enabled Health Technologies
DESCRIPTION
The 2026 Jt. Commission (JCAHO) Ambulatory National Patient Safety Goals include correct patient identification, prevention of surgical mistakes and infections, and the safe use of medications. Other national patient safety groups emphasize concerns with newer health information technology, including AI scribe function, clinical decision support, patient support chatbots and the proliferation of journal paper mills. Associated AI risks include charting errors, hallucinations, speech accent bias, clinical deskilling, patient privacy, informed consent, and ethical, regulatory, and medical-legal issues. It’s also critical for physicians to know AI patient privacy issues and key questions to ask the many AI vendors.
LEARNING OBJECTIVES
Summarize clinical pearls from JCAHO National Patient Safety Goals and ongoing patient safety issues, including prevention of wrong-site procedures, and risks of AI generated paper mills and predatory journals
Summarize clinical pearls of patient safety risks associated with AI- enabled Health Information Technologies, including AI-Scribes, Clinical Decision Support, and accountability for errors and data breaches
SCHEDULE
8:45 AM
Patient Safety / AI Pearls Session # 1
James S. Taylor, MD, FAAD
9:07 AM
Patient Safety / AI Pearls Session # 2
Jane Margaret Grant-Kels, MD, FAAD
DIRECTOR
James S. Taylor, MD, FAAD
Cleveland Clinic and Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
SPEAKER
Jane Margaret Grant-Kels, MD, FAAD
University of Connecticut School of Medicine, Department of Dermatology; University of Florida College of Medicine, Department of Dermatology
DISCLOSURES
Jane Margaret Grant-Kels, MD, FAAD
No financial relationships exist with ineligible companies.
James S. Taylor, MD, FAAD
AstraZeneca – Stockholder Public Company(Stock); Cigna – Stockholder Public Company(Stock); Johnson & Johnson Consumer Products Company – Stockholder Public Company(Stock); Kao Brands – Consultant (1099 relationship)(Grants/Research Funding); Merck & Co., Inc. – Stockholder Public Company(Stock); OPKO Health, Inc. – Stockholder Public Company(Stock); Organon & Co. – Stockholder Public Company(Stock); US Food and Drug Administration, Center for Devices and Radiological Health – Other(Honoraria);